Adamas Pharmaceuticals Shares Jump

Adamas Pharmaceuticals Shares Jump

Adamas Pharmaceuticals shares opened 47% higher Friday to a 20-month high after the company said late Thursday the U.S. Food and Drug Administration (FDA) has approved Gocovri extended release capsules for treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Gocovri, previously granted orphan drug status by the FDA, is the first and only medicine approved by the FDA for this indication. […]

Read More ˃